Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (2014)	2/13/2002 3:43:06 PM
From: Cacaito	Read Replies (1) \| Respond to of 2515

"We are extremely disappointed with your response to our proposal of February 5th. Clearly, we have a fundamentally different view of the serious issues created by U. S. Food and Drug Administration's (FDA) refusal to file letter, subsequent events and the appropriate course of action to take, including who should lead the effort going forward." Bmy is upset not only with refusal, but also for the "subsequent events", my interpratation is that the way sam reported the RTF and the incoming suits and investigation are a big part of the BMY case. Of course, it provezs an ongoing way of dealing with partneres call them BMY, analists, shareholders media, agencies. Bmy id building its case against imcl.